BusinessBeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 5:15 PM UTC
BusinessBeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 2:00 PM UTC
BusinessBeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111By Nasdaq OMXNov 13, 2017, 9:05 PM UTC
BusinessBeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXNov 1, 2017, 1:02 PM UTC
BusinessBeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111By Nasdaq OMXJun 16, 2017, 9:50 AM UTC
BusinessBeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant LymphomaBy Nasdaq OMXJun 15, 2017, 2:00 PM UTC
BusinessBeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant LymphomaBy Nasdaq OMXJun 14, 2017, 10:00 AM UTC
BusinessBeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference CallBy Nasdaq OMXJun 7, 2017, 4:00 PM UTC
